Amylyx Pharmaceuticals, Inc.
AMLX
$14.05
$0.261.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -665.00K | -249.00K | -1.27M | 87.37M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -665.00K | -249.00K | -1.27M | 87.37M |
| Cost of Revenue | 6.96M | -3.24M | -1.05M | 2.50M | 133.39M |
| Gross Profit | -6.96M | 2.58M | 803.00K | -3.77M | -46.02M |
| SG&A Expenses | 62.89M | 64.59M | 66.25M | 72.26M | 114.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 153.29M | 156.68M | 160.52M | 170.08M | 343.05M |
| Operating Income | -153.29M | -157.34M | -160.77M | -171.35M | -255.68M |
| Income Before Tax | -144.69M | -149.92M | -188.24M | -219.49M | -302.14M |
| Income Tax Expenses | 46.00K | -635.00K | -635.00K | -635.00K | -393.00K |
| Earnings from Continuing Operations | -144.74 | -149.28 | -187.60 | -218.86 | -301.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -144.74M | -149.28M | -187.60M | -218.86M | -301.74M |
| EBIT | -153.29M | -157.34M | -160.77M | -171.35M | -255.68M |
| EBITDA | -152.77M | -156.76M | -160.09M | -170.61M | -254.77M |
| EPS Basic | -1.55 | -1.80 | -2.50 | -3.10 | -4.43 |
| Normalized Basic EPS | -1.00 | -1.22 | -1.33 | -1.49 | -2.32 |
| EPS Diluted | -1.55 | -1.80 | -2.50 | -3.10 | -4.43 |
| Normalized Diluted EPS | -1.00 | -1.22 | -1.33 | -1.49 | -2.32 |
| Average Basic Shares Outstanding | 378.01M | 336.76M | 311.52M | 290.41M | 272.56M |
| Average Diluted Shares Outstanding | 378.01M | 336.76M | 311.52M | 290.41M | 272.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |